Sanofi’s Revamped Business Structure Includes Three New Pharma Units
This article was originally published in The Pink Sheet Daily
Executive Summary
The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.
You may also be interested in...
Longtime Genzyme Holdout Meeker Passes Reigns To Sibold
Bill Sibold will take over the leadership of Sanofi's Cambridge-based Genzyme group as the unit begins the important launch of Dupixent. Meeker ends his career at Genzyme after 23 years.
Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.